Fig. 7.
Fig. 7. Autologous mature DCs pulsed with autologous or allogeneic EBV B-LCL freeze–thaw lysates stimulate anti-EBV CD8+ CTL in vitro. / Purified CD8+ lymphocytes from EBV-seropositive donor IP3 were stimulated with autologous DCs loaded with freeze–thaw lysates prepared from autologous IP3 EBV B-LCL (A) or allogeneic IP2 EBV B-LCL (B) as described in “Materials and methods” and Figure 6. Six-hour51Cr-release assays were performed on day 24 (10 days after restimulation on day 14). K562 cells were not added as cold-target inhibitors because T-cell specific lysis of K562 was less than 5% at all effector-to-target ratios (data not shown). The percent specific lysis is reported against IP1 EBV B-LCL (▪), IP2 EBV B-LCL (▿), IP3 EBV B-LCL (●), IP3 EBV B-LCL in the presence of blocking mAb directed against MHC class I (W6/32, ○) or MHC class II (L243, ▾) molecules, or IP3 T blasts (■). Donors IP1, IP2, and IP3 are completely mismatched for HLA class I.

Autologous mature DCs pulsed with autologous or allogeneic EBV B-LCL freeze–thaw lysates stimulate anti-EBV CD8+ CTL in vitro.

Purified CD8+ lymphocytes from EBV-seropositive donor IP3 were stimulated with autologous DCs loaded with freeze–thaw lysates prepared from autologous IP3 EBV B-LCL (A) or allogeneic IP2 EBV B-LCL (B) as described in “Materials and methods” and Figure 6. Six-hour51Cr-release assays were performed on day 24 (10 days after restimulation on day 14). K562 cells were not added as cold-target inhibitors because T-cell specific lysis of K562 was less than 5% at all effector-to-target ratios (data not shown). The percent specific lysis is reported against IP1 EBV B-LCL (▪), IP2 EBV B-LCL (▿), IP3 EBV B-LCL (●), IP3 EBV B-LCL in the presence of blocking mAb directed against MHC class I (W6/32, ○) or MHC class II (L243, ▾) molecules, or IP3 T blasts (■). Donors IP1, IP2, and IP3 are completely mismatched for HLA class I.

Close Modal

or Create an Account

Close Modal
Close Modal